How many drugs treat Severe Recalcitrant Psoriasis?

Drug Landscape tracks 7 marketed treatments for Severe Recalcitrant Psoriasis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/severe-recalcitrant-psoriasis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Severe Recalcitrant Psoriasis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Severe Recalcitrant Psoriasis (disease) competitive landscape: 7 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

7 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Severe Recalcitrant Psoriasis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Soriatane	ACITRETIN	Stiefel Labs Inc	Retinoid [EPC]	Bile salt export pump	1996-01-01
Sandimmune	cyclosporine	Novartis AG (originally Sandoz)	Calcineurin inhibitor (immunosuppressant)	Calcineurin subunit B type 1, Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2	1983-11-14
Sandimmune	Ciclosporin	Novartis	Calcineurin Inhibitor Immunosuppressant [EPC]	Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform	1983-01-01
Oxsoralen-Ultra	METHOXSALEN	Bausch Health	Photoactivated Radical Generator [EPC]	Cytochrome P450 1A2	1954-01-01
Neoral	Neoral	Novartis Pharmaceuticals		Calcineurin subunit B type 1, Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2
Cyclosporin	Cyclosporin	Karolinska University Hospital		Calcineurin subunit B type 1, Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2
ciclosporine	ciclosporine	Hospices Civils de Lyon		Calcineurin subunit B type 1, Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Bausch Health · 1 drug in Severe Recalcitrant Psoriasis
Hospices Civils de Lyon · 1 drug in Severe Recalcitrant Psoriasis
Karolinska University Hospital · 1 drug in Severe Recalcitrant Psoriasis
Novartis · 1 drug in Severe Recalcitrant Psoriasis
Novartis AG (originally Sandoz) · 1 drug in Severe Recalcitrant Psoriasis
Novartis Pharmaceuticals · 1 drug in Severe Recalcitrant Psoriasis
Stiefel Labs Inc · 1 drug in Severe Recalcitrant Psoriasis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Severe Recalcitrant Psoriasis:

Cite this brief

Drug Landscape (2026). Severe Recalcitrant Psoriasis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/severe-recalcitrant-psoriasis. Accessed 2026-06-10.

Severe Recalcitrant Psoriasis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing